Roivant Sciences ROIV
NASDAQ ROIV
$36.30 -0.54 (-1.47%)
At close: Aug 21, 2026 · 4:00 PM EDT

Roivant Sciences (ROIV) Interest & Investment Income (2021 - 2026)

Roivant Sciences' (ROIV) quarterly Interest & Investment Income came in at $136.9 million in Q4 2025, down 32.8% YoY from $203.8 million in Q4 2024, and up 5205.27% on a QoQ basis from $2.6 million in Q3 2025.

Roivant Sciences (ROIV) Interest & Investment Income (2021 - 2026) Analysis & Trends

Roivant Sciences (ROIV) has 5 years of Interest & Investment Income data on file, last reported at $136.9 million in Q4 2025.

  • Quarterly Interest & Investment Income fell 32.8% year-over-year to $136.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $343.7 million (down 15.88% YoY) and the FY2026 annual result came in at $178.1 million, down 31.07% from the prior year.
  • Interest & Investment Income improved to $136.9 million in Q4 2025, from $2.6 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $203.8 million in Q4 2024 to a low of $62000.0 in Q3 2021.
  • A 5-year average of $43.2 million and a median of $15.5 million in 2023 frame the typical range for Interest & Investment Income.
  • Annual changes were most pronounced in 2022 — Interest & Investment Income surged 9045.16% — and 2025, when it plunged 99.35%.
  • Tracing ROIV's Interest & Investment Income over 5 years: stood at $199000.0 in 2021, then soared by 8894.97% to $17.9 million in 2022, then jumped by 251.77% to $63.0 million in 2023, then jumped by 223.58% to $203.8 million in 2024, then tumbled by 32.8% to $136.9 million in 2025.
  • The last three Interest & Investment Income figures came in at $136.9 million (Q4 2025), $2.6 million (Q3 2025), and $470000.0 (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int & Inv Inc (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 120.60 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -48.00 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 48.00 Mn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 67.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 27.90 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 28.14 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 115.94 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 10.98 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 5.13 Mn
10 Roivant Sciences 26.20 Bn 26.20 Bn 1.16 Mn 36.92 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 36.92 Mn
Dec 31, 2025 136.93 Mn
Sep 30, 2025 2.58 Mn
Jun 30, 2025 470,000.00
Dec 31, 2024 203.75 Mn
Sep 30, 2024 69.77 Mn
Jun 30, 2024 72.13 Mn
Dec 31, 2023 62.97 Mn
Sep 30, 2023 14.30 Mn
Jun 30, 2023 16.72 Mn
Dec 31, 2022 17.90 Mn
Sep 30, 2022 5.67 Mn
Jun 30, 2022 1.98 Mn
Dec 31, 2021 199,000.00
Sep 30, 2021 62,000.00